Rafael Holdings takes majority stake in Rafael Pharmaceuticals

24 January 2019

New Jersey, USA-based Rafael Holdings (NYSE: RFL) has bought a majority stake in Rafael Pharmaceuticals, building on prior investments in the metabolic oncology-therapeutics firm.

The total investment to date from Rafael Holdings in Rafael Pharma now amounts to $66.7 million, equating to a 51% stake in the company.

Howard Jonas, chief executive of Rafael Holdings, said: "We continue to invest in Rafael Pharma to support the promising clinical development of its lead drug, devimistat (CPI-613), as well as other Rafael Pharma agents now in pre-clinical development that have been discovered from its Altered Metabolism Directed platform.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK